PREvent First Episode Relapse (PREFER)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2008 by State University of New York - Downstate Medical Center.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Janssen, LP
Information provided by:
State University of New York - Downstate Medical Center
ClinicalTrials.gov Identifier:
NCT00220714
First received: September 13, 2005
Last updated: March 28, 2008
Last verified: March 2008
  Purpose

Many patients who have recently received a diagnosis of schizophrenia (e.g., "first-episode schizophrenia") respond very well to their antipsychotic medication when they are acutely ill. Once they are more stable, research has shown that first-episode patients need to remain on their antipsychotic medication. Follow-up studies show that stopping medication prematurely is the most common cause of relapse and readmission. It is important to have new ways to help patients stay stable in the community in order for them to continue on with their rehabilitation and recovery process.

Over the last decade, new antipsychotic medications have been developed that are more effective and have fewer side effects than older antipsychotics. The new medicines are often called "atypical", and were only available by pill or capsule for long-term treatment. Most recently, one of the atypical medications - risperidone - became available as a long-acting injection that can be given once every 2 weeks.

The hypothesis of this study is that patients recovering from an acute episode and who then go on to receive a long-acting version of atypical antipsychotic medication (long-acting risperidone microspheres) will stay on their medications for longer than those who take their atypical medication (any available first-line atypical) in the oral (pill) form.


Condition Intervention Phase
Schizophrenia
Drug: atypical antipsychotics:oral vs. long-acting route
Behavioral: Family Psychoeducation
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effectiveness of Long-Acting Risperidone in the Maintenance Treatment of First-Episode Schizophrenia

Resource links provided by NLM:


Further study details as provided by State University of New York - Downstate Medical Center:

Primary Outcome Measures:
  • Likelihood of accepting a recommendation of long-acting atypical antipsychotic medication
  • Compare the time until the first episode of antipsychotic nonadherence as defined by 2 or more weeks of continuous and intentional cessation of all prescribed antipsychotic medication
  • Compare the total amount of outpatient days spent adherent to antipsychotic medication as a proportion of outpatient days in the study
  • Compare patient and family attitudes and satisfaction with antipsychotic medication given by long-acting route vs. oral route of drug delivery
  • 5. Modify and adapt psychoeducational material designed for multiple episode patients to better fit the needs of recently diagnosed patients with schizophrenia.

Secondary Outcome Measures:
  • Compare the likelihood of relapse and rehospitalization between long-acting atypical antipsychotic with all available first-line oral atypical agents
  • Compare the longitudinal course of symptoms and side effects of those remaining on long-acting atypicals to those remaining on oral antipsychotic regimens
  • Compare outcome differences between intent-to-treat assignments with actual observed treatment groups

Estimated Enrollment: 80
Study Start Date: November 2004
Estimated Study Completion Date: December 2007
Detailed Description:

Overview: Before the atypicals were introduced, some of the older antipsychotics were available in oral (pill or capsule) and long-acting (depot) versions. Despite the potential advantages of the depot versions, in those days clinicians in the United States have historically limited the use of long-acting, "depot" antipsychotics to their most treatment-resistant, chronic, patients. Therefore, most clinicians did not routinely consider starting a long-acting antipsychotic early in the course of treatment, such as after the first-episode of schizophrenia.

This whole issue was less relevant after the atypical medications came out, because they were only available in oral versions for long-term treatment. Now that one of the atypical medications (risperidone) is available for use in the United States, the issue of appropriate use of oral vs. long-acting atypical is now very relevant to clinical practice.

For first episode patients, there are been two issues that suggest that the route of medication delivery is an important area to study. First is that almost all first-episode patients will stop their medication too soon. Second, a there now is atypical antipsychotic available in a long-acting preparation (long-acting risperidone, but this option is not often used right away after a first episode, so there is little guidance for clinicians about the effectiveness of long-acting antipsychotics used right away after a first-episode.

Methods: This study compares the effectiveness of the long-acting route of medication to improve adherence and reduce relapse among patients who have been recently diagnosed with schizophrenia or a related psychotic disorder. After patients are stabilized with an atypical antipsychotic and have received patient and family psychoeducation, consenting patients will be randomized to a prospective, random-assignment open-label study comparing any available first-line oral atypical antipsychotic to long-acting risperidone for the maintenance treatment of patients recovering from acute treatment of first-episode schizophrenia.

This study is divided into three study phases. Study Phase I is the acute phase, where consenting patients would be given an acute open-label trial of an oral antipsychotic. Patients who respond within a maximum of 12 weeks to acute therapy will then be invited to participate in Phase II of the study. Patients agreeing to Phase II will then be randomized into staying on their oral antipsychotic medication vs. switching to a long-acting atypical antipsychotic (long-acting risperidone). Patients would be followed for 12 weeks to determine whether or not they accept a recommendation of long-acting antipsychotic or continued oral antipsychotic. Then patients enter into Study Phase III, where they are followed for at the remainder of the year. We want to learn how often patients will accept their doctor's recommendation of a long-acting injection, whether persons taking their antipsychotic medication in long-acting form do better in terms of willingness to stay on their medication, or have better symptom control or fewer side effects, than persons where the doctor recommends the medication in oral (pill) form.

Summary: Patients recently diagnosed as suffering from schizophrenia, e.g. the "first-episode" patient might benefit from an atypical antipsychotic given in a long-acting route of drug- delivery. However, long-acting antipsychotic therapy is not routinely considered in first-episode patients. Studying the acceptance and ultimate effectiveness of a long-acting atypical antipsychotic would be very helpful in understanding how to help patients stay stable and ultimately prevent a revolving door pattern that, if it continues, can be devastating to the recovery process.

  Eligibility

Ages Eligible for Study:   16 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

There is a 2 step inclusion/exclusion criteria, the first being for assessing overall eligibility to be enter, and then, for continued outpatient treatment for schizophrenia when clinically appropriate.

Inclusion criteria for the first phase:

  1. Between 16-50 years of age
  2. Psychotic symptoms must have persisted at least one month prior to starting the current antipsychotic
  3. Continue to show some positive (psychotic) symptoms of schizophrenia
  4. A provisional clinical diagnosis of schizophreniform disorder,schizophrenia, or schizoaffective disorder
  5. Confirm that there was no previous history of significant pharmacological treatment with an antipsychotic medication
  6. Able to fully participate in the informed consent process

Exclusion criteria for Study Phase I

  1. Unable to understand informed consent process
  2. A history of nonresponse to, or severe adverse events from, any prior exposure to oral risperidone
  3. Will not be living close enough to the medical center to return for follow-up visits or assessments
  4. Currently receiving medication over objection by court order

Inclusion criteria for Study Phase II

Key criteria for entry into Study Phase II are:

  1. Has clinically responded to the oral antipsychotic regimen
  2. Willingness to transition to receive evaluation and future pharmacologic treatment at the Schizophrenia Research Service
  3. Has retained capacity to understand the risks and benefits of the maintenance treatment with antipsychotics
  4. Willingness to sign informed consent to go into Study Phase II

Exclusion criteria for Study Phase II

  1. Has not responded to the current oral antipsychotic regimen, or has had significant side effects to oral risperidone
  2. Explicit refusal to even consider the possibility of receiving maintenance antipsychotic by long-acting injection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00220714

Locations
United States, New York
SUNY Downstate Medical Center
Brooklyn, New York, United States, 11203
Kings County Hospital Center
Brooklyn, New York, United States, 11203
Sponsors and Collaborators
State University of New York - Downstate Medical Center
Janssen, LP
Investigators
Principal Investigator: Peter J Weiden, M.D. State University of New York - Downstate Medical Center
  More Information

No publications provided by State University of New York - Downstate Medical Center

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00220714     History of Changes
Other Study ID Numbers: RIS-SCH-420
Study First Received: September 13, 2005
Last Updated: March 28, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by State University of New York - Downstate Medical Center:
schizophrenia
first-episode
patient compliance
long-acting risperidone
relapse

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Antipsychotic Agents
Risperidone
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Dopamine Antagonists
Dopamine Agents

ClinicalTrials.gov processed this record on August 27, 2014